MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

35.32 -0.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.96

Massimo

35.45

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.12% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	137M 5.7B
Apertura precedente	35.43
Chiusura precedente	35.32

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2026, 17:11 UTC

I principali Market Mover

Principali Notizie su Eventi

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 apr 2026, 17:10 UTC

Principali Notizie su Eventi

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 apr 2026, 00:00 UTC

Principali Notizie su Eventi

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 apr 2026, 23:47 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 apr 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 apr 2026, 21:01 UTC

Principali Notizie su Eventi

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 apr 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

2 apr 2026, 20:41 UTC

Utili

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 20:32 UTC

Discorsi di Mercato

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 apr 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 20:09 UTC

Discorsi di Mercato

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 apr 2026, 20:01 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:46 UTC

Discorsi di Mercato

Is Oil the New GameStop? -- Market Talk

2 apr 2026, 19:35 UTC

Discorsi di Mercato

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 apr 2026, 19:29 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:24 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 apr 2026, 19:20 UTC

Discorsi di Mercato

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 apr 2026, 19:01 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 apr 2026, 19:00 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 apr 2026, 18:24 UTC

Acquisizioni, Fusioni, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 apr 2026, 17:44 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 apr 2026, 17:32 UTC

Principali Notizie su Eventi

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 apr 2026, 17:26 UTC

Utili

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 17:17 UTC

Discorsi di Mercato

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 apr 2026, 17:09 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

49.12% in crescita

Previsioni per 12 mesi

Media 52.55 USD 49.12%

Alto 64 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.